Search Results 441-450 of 18036 for Alopecia

1. A Phase 1B Dose-escalation Study of TRC105 in Combination With Pazopanib in Patients With Advanced Soft Tissue Sarcoma - Mayo Clinic

   Resolution of all acute adverse events resulting from prior cancer therapies to NCI CTCAE grade ≤ 1 or baseline (except alopecia or neuropathy); Adequate ...

2. Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab (DeLLphi-305) - Mayo Clinic

   * Toxicities attributed to prior anti-cancer therapy resolved to grade ≤ 1, unless otherwise specified, excluding alopecia or fatigue. * Adequate organ ...

3. Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Chondrosarcoma - Mayo Clinic

   Any ongoing toxicity from prior anti-cancer therapy that is > Grade 1 and/or that is progressing in severity, except alopecia. Known immediate or delayed ...

4. Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors - Mayo Clinic

   ... alopecia -Receiving any other investigational agents =< 28 days prior to registration -Known brain metastases (even if treated) -Known portal hypertension ...

5. Loncastuximab Tesirine in WM - Mayo Clinic

   Participants with ongoing >grade 1 toxicities from prior therapy (alopecia any grade and/or grade 2 neuropathy are permitted). - Participants with ...

6. A Study of Trametinib in Treating Patients With Epithelioid Hemangioendothelioma That Is Metastatic, Locally Advanced, or Cannot Be Removed by Surgery - Mayo Clinic

   All prior treatment-related toxicities must be Common Terminology Criteria for Adverse Events version 5.0 (CTCAE v5) grade =< 1 (except alopecia) at the time of ...

7. Evaluate The Safety, Tolerability, Pharmacokinetics And Efficacy Of BL-M05D1 In Subjects With Solid Tumors - Mayo Clinic

   ... alopecia and endocrinopathies controlled by replacement therapy that must be Grade ≤2 9. Has no serious cardiac dysfunction, left ventricular ejection ...

8. Study Of Datopotamab Deruxtecan Plus Carboplatin Or Cisplatin Versus Gemcitabine Plus Carboplatin Or Cisplatin In Participants With Locally Advanced Or Metastatic Urothelial Carcinoma - Mayo Clinic

   Toxicities from previous anticancer therapy, defined as toxicities (other than alopecia) not yet improved to NCI-CTCAE version 5.0 Grade ≤1 or baseline.

9. A Study to Compare the Effectiveness and Safety of bb2121 Versus Standard Regimens in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM) - Mayo Clinic

   Recovery to Grade 1 or baseline of any non-hematologic toxicities due to prior treatments, excluding alopecia and Grade 2 peripheral neuropathy. Exclusion ...

10. Study of Pazopanib in the Treatment of Osteosarcoma Metastatic to the Lung - Mayo Clinic

    Any ongoing toxicity from prior anti-cancer therapy that is > Grade 1 and/or that is progressing in severity, except alopecia. An untreated tumor growth ...